Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies
Objective We aimed to evaluate the robustness of phase III randomised controlled trials (RCTs) for SLE and lupus nephritis (LN) using the fragility index (FI), the reverse FI (RFI) and the fragility quotient (FQ).Methods We searched for phase III RCTs that included patients with active SLE or LN. Da...
| Prif Awduron: | , , , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
BMJ Publishing Group
2024-05-01
|
| Cyfres: | Lupus Science and Medicine |
| Mynediad Ar-lein: | https://lupus.bmj.com/content/11/1/e001068.full |